Lead Asset Anti-LLT1 mAb (Potential first-in-class antibody targeting LLT1-Lectin Like Transcript 1)
mAb target. Functions through tumour associated antigen/NK cell receptor
mAb target. Functions through tumour NK cell receptor
Molecules for NK cell and cell targets under development
In vivo efficacy study completed
Selection of Ab producing stable cell lines. Process development large scale manufacture
Stability studies,
CMC Package Development